Boehringer Ingelheim has announced new data analyses from the pivotal Phase III TONADO 1&2 studies, which explored the efficacy and...
Boehringer Ingelheim presented the first data from the pivotal Phase III TONADO 1&2 studies (NCT01431274/NCT01431287) for the fixed-dose combination (FDC)...
Boehringer Ingelheim announced regulatory authority approvals for Spiolto Respimat (tiotropium/olodaterol) in first European countries. Spiolto Respimat is a once-daily maintenance...
The FDA approved a sNDA for Stiolto Respimat (olodaterol + tiotropium), from Boehringer, that adds data showing improvement in health-related...
Boehringer Ingelheim has announced that the FDA accepted for review the New Drug Application (NDA) for the fixed-dose combination (FDC)...
Boehringer Ingelheim announced that the FDA approved once-daily Stiolto Respimat (tiotropium bromide and olodaterol) Inhalation Spray as a long-term, once-daily...
The FDA has approved Spiriva Respimat (tiotropium bromide) inhalation spray, from Boehringer, for the long-term, once-daily maintenance treatment of bronchospasm...
Boehringer has submitted Marketing Authorisation Applications in 31 European countries for the once-daily, fixed-dose Respimat Soft Mist Inhaler (tiotropium +...
Tiotropium is a long-acting inhaled anticholinergic developed for the treatment of chronic obstructive pulmonary disease (COPD) and has been available since 2002.
Boehringer announced that data from the DYNAGITO trial, a 52-week study involving more than 7,800 people across a broad range...